Study of pimavanserin (Acadia Pharma) in PDP published in The Lancet

Data from a pivotal Phase III -020 Study with pimavanserin, from Acadia Pharma, in patients with Parkinson�s Disease Psychosis (PDP) demonstrated significant and clinically meaningful benefits and was safe and well tolerated in patients with PDP. Pimavanserin met the primary endpoint in the -020 Study by demonstrating highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale (p=0.001), which was assessed by central, independent raters. The mean change in SAPS-PD score represented a 37% improvement for pimavanserin versus 14% for placebo (p<0.001).>

Significant benefits were also observed in exploratory measures of nighttime sleep, daytime wakefulness and caregiver burden. The data is published in The Lancet. See: "Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial" Jeffrey Cummings et al. November 1, 2013 online issue.